Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 6, 2012, Pages 477-486

  Lech Maranda, Ewa ^a,b   Grzybowska Izydorczyk, Olga ^b   Wyka, Krystyna ^b   Mlynarski, Wojciech ^b   Borowiec, Maciej ^b   Antosik, Karolina ^b   Cebula Obrzut, Barbara ^b   Makuch Lasica, Hanna ^a   Nowak, Grazyna ^a   Klimkiewicz Wojciechowska, Gabriela ^b   Wawrzyniak, Ewa ^b   Bilinski, Przemyslaw ^a,c   Robak, Tadeusz ^b   Warzocha, Krzysztof ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Department Sanitary Inspectorate ^*  (Poland)

Author keywords

Chronic lymphocytic leukemia; Immunoglobulin heavy chain variable region genes; Interleukin 10; Outcome; Tumor necrosis factor

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; HEMOGLOBIN; INTERLEUKIN 10; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT FREE SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84872103461     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0197-7     Document Type: Article

References (28)

1. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC (1993) Serum interleukin-10 in non- Hodgkin's lymphoma: a prognostic factor. Blood 82:2169-2174
2. Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszynska A, Rolinski J (2008) Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res 32:225-233
3. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997
4. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915-924
5. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97:256-263
6. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M (2002) The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100:1215-1219
7. Fluckiger AC, Durand I, Banchereau J (1994) Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 179:91-99
8. Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF, Fierro MT (1990) Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76:393-400
9. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P (2011) CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 15:4835-4844
10. Gruss HJ, Dower SK (1995) Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 85:3378-3404
11. Jablonska E, Kiersnowska-Rogowska B, Rogowski F, Parfienczyk A, Puzewska W, Bukin M (2005) TNF family molecules in the serum of patients with B-cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 46:1307-1312
12. Kipps TJ (2000) Chronic lymphocytic leukemia. Curr Opin Hematol 7:223-234
13. KitabayashiA,HirokawaM,MiuraAB(1995) The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Int J Hematol 62:99-106
14. Klein U, Dalla-Favera R (2010) New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 20:377-383
15. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G (2010) Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-cell lymphoma in different risk groups defined by the international prognostic index. Arch Immunol Ther Exp 58:131-141
16. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61-76
17. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765
18. Rath PC, Aggarwal BB (1999) TNF-induced signaling in apoptosis. J Clin Immunol 19:350-364
19. Riches JC, Ramsay AG, Gribben JG (2010) T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 20:431-438
20. Robak T, Blonski JZ, Wawrzyniak E, Gora-Tybor J, Palacz A, Dmoszynska A, Konopka L, Warzocha K, Jamroziak K (2009) Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. Cancer 115:94-100
21. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ (2010) Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALGCLL3 Study). J Clin Oncol 28:1863-1869
22. Tangye SG, Weston KM, Raison RL (1998) Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD5+ B-cells. Leuk Lymphoma 31:121-130
23. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317
24. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499-5505
25. Wanidworanun C, Strober W (1993) Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 151:6853-6861
26. Warzocha K, Salles G (1998) The tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferation. Leuk Lymphoma 29:81-92
27. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard EM, Coiffier B (1997) Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 15:499-508
28. Younes A, Aggarwall BB (2003) Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 98:458-467